

# Comparative Efficacy of Inactivated and Live Attenuate

New England Journal of Medicine

361, 1260-1267

DOI: [10.1056/nejmoa0808652](https://doi.org/10.1056/nejmoa0808652)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Anti-Influenza Serum and Mucosal Antibody Responses After Administration of Live Attenuated or Inactivated Influenza Vaccines to HIV-Infected Children. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2010, 55, 189-196.	0.9	41
2	The Efficacy of Live Attenuated and Inactivated Influenza Vaccines in Children as a Function of Time Postvaccination. <i>Pediatric Infectious Disease Journal</i> , 2010, 29, 806-811.	1.1	53
3	Review: Extended-duration chemoprophylaxis with neuraminidase inhibitors prevents symptomatic influenza. <i>Annals of Internal Medicine</i> , 2010, 152, JC3.	2.0	0
4	How I treat influenza in patients with hematologic malignancies. <i>Blood</i> , 2010, 115, 1331-1342.	0.6	109
5	Influenza vaccines provide diminished protection but are cost-saving in older adults. <i>Journal of Internal Medicine</i> , 2010, 267, 220-227.	2.7	35
6	Efficacy of live attenuated influenza vaccine in children 6 months to 17 years of age. <i>Influenza and Other Respiratory Viruses</i> , 2010, 4, 141-145.	1.5	47
7	Seasonal Influenza Vaccine and Protection against Pandemic (H1N1) 2009-Associated Illness among US Military Personnel. <i>PLoS ONE</i> , 2010, 5, e10722.	1.1	63
8	Flexible Label-Free Quantitative Assay for Antibodies to Influenza Virus Hemagglutinins. <i>Vaccine Journal</i> , 2010, 17, 1407-1416.	3.2	22
9	A 29-Year-Old Woman With Flu-like Symptoms. <i>JAMA - Journal of the American Medical Association</i> , 2010, 304, 671.	3.8	4
10	Poor immunogenicity of the H1N1 2009 vaccine in well controlled HIV-infected individuals. <i>Aids</i> , 2010, 24, 2187-2192.	1.0	123
11	Comparative Efficacy of Influenza Vaccines. <i>New England Journal of Medicine</i> , 2010, 362, 179-181.	13.9	2
13	Report of the fourth meeting on "Influenza vaccines that induce broad spectrum and long-lasting immune responses", World Health Organization and Wellcome Trust, London, United Kingdom, 9-10 November 2009. <i>Vaccine</i> , 2010, 28, 3875-3882.	1.7	22
14	Seasonal influenza vaccinations: specialized products for different target groups. <i>Vaccine</i> , 2010, 28, D14-D23.	1.7	5
15	Pandemic and seasonal H1N1 influenza hemagglutinin-specific T cell responses elicited by seasonal influenza vaccination. <i>Vaccine</i> , 2010, 28, 8258-8267.	1.7	48
17	Cross-protective immunity to influenza A viruses. <i>Expert Review of Vaccines</i> , 2010, 9, 1325-1341.	2.0	105
18	Are Anti-Infectious Vaccinations Safe and Effective in Patients with Autoimmunity?. <i>International Reviews of Immunology</i> , 2010, 29, 270-314.	1.5	36
19	Intanza <sup>®</sup> : a new intradermal vaccine for seasonal influenza. <i>Expert Review of Vaccines</i> , 2010, 9, 1399-1409.	2.0	53
20	Serologic assays for influenza surveillance, diagnosis and vaccine evaluation. <i>Expert Review of Anti-Infective Therapy</i> , 2011, 9, 669-683.	2.0	196

#	ARTICLE	IF	CITATIONS
21	Live Attenuated Influenza Virus Vaccines: NS1 Truncation as an Approach to Virus Attenuation. , 2011, , 195-221.		0
22	Live Attenuated Influenza Vaccine (FluMist®; Fluenzâ„¢). Drugs, 2011, 71, 1591-1622.	4.9	189
23	Influenza vaccine responses in older adults. Ageing Research Reviews, 2011, 10, 379-388.	5.0	145
24	CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults. Biology of Blood and Marrow Transplantation, 2011, 17, 524-533.	2.0	5
25	Comparison of antibody and T-cell responses elicited by licensed inactivated- and live-attenuated influenza vaccines against H3N2 hemagglutinin. Human Immunology, 2011, 72, 463-469.	1.2	45
26	An M2 cytoplasmic tail mutant as a live attenuated influenza vaccine against pandemic (H1N1) 2009 influenza virus. Vaccine, 2011, 29, 2308-2312.	1.7	19
27	Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok®) against influenza in healthy adults: A randomized, placebo-controlled trial. Vaccine, 2011, 29, 7733-7739.	1.7	130
28	A systematic review of the evidence on the effectiveness and risks of inactivated influenza vaccines in different target groups. Vaccine, 2011, 29, 9159-9170.	1.7	133
29	Vaccine effectiveness for laboratory-confirmed influenza in children 6â€“59 months of age, 2005â€“2007. Vaccine, 2011, 29, 9005-9011.	1.7	33
30	Complete inactivation of HIV-1 using photo-labeled non-nucleoside reverse transcriptase inhibitors. Virus Research, 2011, 155, 189-194.	1.1	8
31	Effectiveness of inactivated influenza vaccine in children aged 9 months to 3 years: an observational cohort study. Lancet Infectious Diseases, The, 2011, 11, 23-29.	4.6	84
32	Influenza vaccine effectiveness in Wisconsin during the 2007â€“08 season: Comparison of interim and final results. Vaccine, 2011, 29, 6558-6563.	1.7	81
33	Efficacy, safety, and immunogenicity of a Vero-cell-culture-derived trivalent influenza vaccine: a multicentre, double-blind, randomised, placebo-controlled trial. Lancet, The, 2011, 377, 751-759.	6.3	92
34	Respiratory Viral Infections. , 2011, , 378-391.		0
35	Cost-Effectiveness of 2009 Pandemic Influenza A(H1N1) Vaccination in the United States. PLoS ONE, 2011, 6, e22308.	1.1	37
36	Effectiveness of Non-Adjuvanted Pandemic Influenza A Vaccines for Preventing Pandemic Influenza Acute Respiratory Illness Visits in 4 U.S. Communities. PLoS ONE, 2011, 6, e23085.	1.1	103
37	Vaccination of adults with asthma and COPD. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 25-31.	2.7	34
38	Guidelines for the management of adult lower respiratory tract infections - Summary. Clinical Microbiology and Infection, 2011, 17, 1-24.	2.8	281

#	ARTICLE	IF	CITATIONS
39	Guidelines for the management of adult lower respiratory tract infections - Full version. <i>Clinical Microbiology and Infection</i> , 2011, 17, E1-E59.	2.8	721
40	DNA vaccines: an historical perspective and view to the future. <i>Immunological Reviews</i> , 2011, 239, 62-84.	2.8	384
41	Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial. <i>European Journal of Clinical Nutrition</i> , 2011, 65, 501-507.	1.3	148
42	The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. <i>Influenza and Other Respiratory Viruses</i> , 2011, 5, 67-75.	1.5	154
43	Influenza: Epidemiology, Clinical Features, Therapy, and Prevention. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2011, 32, 373-392.	0.8	83
44	Disruption of the Viral Polymerase Complex Assembly as a Novel Approach to Attenuate Influenza A Virus. <i>Journal of Biological Chemistry</i> , 2011, 286, 8414-8424.	1.6	31
45	Influenza Vaccines for the Future. , 2011, , .		8
46	Live Attenuated Vaccines: Influenza, Rotavirus and Varicella Zoster Virus. , 2011, , 15-46.		3
47	Seasonal FluMist Vaccination Induces Cross-Reactive T Cell Immunity against H1N1 (2009) Influenza and Secondary Bacterial Infections. <i>Journal of Immunology</i> , 2011, 186, 987-993.	0.4	83
48	Efficacy and correlates of protection for cell culture-derived and egg-derived inactivated influenza vaccines in younger adults. <i>Expert Review of Vaccines</i> , 2011, 10, 1127-1130.	2.0	2
49	Influenza Pandemic Epidemiologic and Virologic Diversity: Reminding Ourselves of the Possibilities. <i>Clinical Infectious Diseases</i> , 2011, 52, S44-S49.	2.9	43
50	Make New Friends, But Keep the Old: Influenza Vaccines in Children With Cancer. <i>Journal of Infectious Diseases</i> , 2011, 204, 1471-1474.	1.9	0
51	Efficacy Studies of Influenza Vaccines: Effect of End Points Used and Characteristics of Vaccine Failures. <i>Journal of Infectious Diseases</i> , 2011, 203, 1309-1315.	1.9	122
52	Influenza Hemagglutination-Inhibition Antibody Titer as a Correlate of Vaccine-Induced Protection. <i>Journal of Infectious Diseases</i> , 2011, 204, 1879-1885.	1.9	246
53	Effectiveness of Seasonal Influenza Vaccines in the United States During a Season With Circulation of All Three Vaccine Strains. <i>Clinical Infectious Diseases</i> , 2012, 55, 951-959.	2.9	227
54	A Cell Culture-Derived Influenza Vaccine Provides Consistent Protection Against Infection and Reduces the Duration and Severity of Disease in Infected Individuals. <i>Clinical Infectious Diseases</i> , 2012, 54, 946-954.	2.9	25
55	Magnitude of Potential Biases in a Simulated Case-Control Study of the Effectiveness of Influenza Vaccination. <i>Clinical Infectious Diseases</i> , 2012, 54, 25-32.	2.9	32
56	Safety of influenza vaccines. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2012, 12, 383-388.	1.1	18

#	ARTICLE	IF	CITATIONS
57	Effectiveness and harms of seasonal and pandemic influenza vaccines in children, adults and elderly. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 851-862.	1.4	76
58	Live attenuated intranasal influenza vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 76-80.	1.4	31
59	New technologies for influenza vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 45-58.	1.4	48
60	Estimates of Influenza Vaccine Effectiveness for 2007â€“2008 From Canada's Sentinel Surveillance System: Cross-Protection Against Major and Minor Variants. <i>Journal of Infectious Diseases</i> , 2012, 205, 1858-1868.	1.9	52
61	Update on Adult Immunizations. <i>Journal of the American Board of Family Medicine</i> , 2012, 25, 496-510.	0.8	13
62	A Sentinel Platform to Evaluate Influenza Vaccine Effectiveness and New Variant Circulation, Canada 2010â€“2011 Season. <i>Clinical Infectious Diseases</i> , 2012, 55, 332-342.	2.9	106
63	Efficacy and effectiveness of influenza vaccines: a systematic review and meta-analysis. <i>Lancet Infectious Diseases</i> , 2012, 12, 36-44.	4.6	1,534
64	A postmarketing evaluation of the safety of Ann Arbor strain live attenuated influenza vaccine in adults 18â€“49 years of age. <i>Vaccine</i> , 2012, 30, 3053-3060.	1.7	28
65	Report of the 5th meeting on influenza vaccines that induce broad spectrum and long-lasting immune responses, World Health Organization, Geneva, 16â€“17 November 2011. <i>Vaccine</i> , 2012, 30, 6612-6622.	1.7	8
66	Randomized comparative study of the serum antihemagglutinin and antineuraminidase antibody responses to six licensed trivalent influenza vaccines. <i>Vaccine</i> , 2012, 31, 190-195.	1.7	69
67	Seasonal influenza vaccine efficacy and its determinants in children and non-elderly adults: A systematic review with meta-analyses of controlled trials. <i>Vaccine</i> , 2012, 31, 49-57.	1.7	137
68	The Use of Live Attenuated Influenza Vaccine (LAIV) in Healthcare Personnel (HCP): Guidance from the Society for Healthcare Epidemiology of America (SHEA). <i>Infection Control and Hospital Epidemiology</i> , 2012, 33, 981-983.	1.0	7
69	Clinical development of a Vero cell culture-derived seasonal influenza vaccine. <i>Vaccine</i> , 2012, 30, 4377-4386.	1.7	24
70	Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. <i>Vaccine</i> , 2012, 30, 1993-1998.	1.7	202
71	Comparative Study of Influenza Virus Replication in MDCK Cells and in Primary Cells Derived from Adenoids and Airway Epithelium. <i>Journal of Virology</i> , 2012, 86, 11725-11734.	1.5	56
72	Benefits of influenza vaccination during pregnancy for pregnant women. <i>American Journal of Obstetrics and Gynecology</i> , 2012, 207, S17-S20.	0.7	35
73	Use of real-time polymerase chain reaction (rtPCR) as a diagnostic tool for influenza infection in a vaccine efficacy trial. <i>Journal of Clinical Virology</i> , 2012, 53, 22-28.	1.6	8
74	Swedish guidelines on the management of community-acquired pneumonia in immunocompetent adultsâ€“Swedish Society of Infectious Diseases 2012. <i>Scandinavian Journal of Infectious Diseases</i> , 2012, 44, 885-902.	1.5	51

#	ARTICLE	IF	CITATIONS
75	Decreased Serologic Response in Vaccinated Military Recruits during 2011 Correspond to Genetic Drift in Concurrent Circulating Pandemic A/H1N1 Viruses. PLoS ONE, 2012, 7, e34581.	1.1	13
76	Balancing the Efficacy and Safety of Vaccines in the Elderly. Open Longevity Science, 2012, 6, 64-72.	0.8	16
78	Cross-reactive humoral responses to influenza and their implications for a universal vaccine. Annals of the New York Academy of Sciences, 2013, 1283, 13-21.	1.8	38
79	Immunogenicity and safety of quadrivalent versus trivalent inactivated influenza vaccine: a randomized, controlled trial in adults. BMC Infectious Diseases, 2013, 13, 224.	1.3	62
80	Comparing influenza vaccine efficacy against mismatched and matched strains: a systematic review and meta-analysis. BMC Medicine, 2013, 11, 153.	2.3	323
81	Influenza vaccine "live. , 2013, , 294-311.		2
82	Editorial Commentary: Influenza Vaccine: Glass Half Full or Half Empty?. Clinical Infectious Diseases, 2013, 56, 1370-1372.	2.9	2
83	Traditional and New Influenza Vaccines. Clinical Microbiology Reviews, 2013, 26, 476-492.	5.7	274
84	Association of HLA class II genes with clinical hyporesponsiveness to trivalent inactivated influenza vaccine in children. Vaccine, 2013, 31, 1123-1128.	1.7	13
85	Background paper to the recommendation for the preferential use of live-attenuated influenza vaccine in children aged 2-6 years in Germany. Bundesgesundheitsblatt - Gesundheitsforschung - Gesundheitsschutz, 2013, 56, 1557-1564.	7.2	12
87	Inactivated influenza vaccines. , 2013, , 257-293.		34
88	Vaccination Among Hospitalized Adults in Acute Care. Hospital Medicine Clinics, 2013, 2, e192-e208.	0.2	0
89	Comparison of the Effectiveness of Trivalent Inactivated Influenza Vaccine and Live, Attenuated Influenza Vaccine in Preventing Influenza-Like Illness Among US Military Service Members, 2006-2009. Clinical Infectious Diseases, 2013, 56, 11-19.	2.9	15
90	Vaccinophobia and Vaccine Controversies of the 21st Century. , 2013, , .		5
91	Management of Influenza in Pregnancy. American Journal of Perinatology, 2013, 30, 099-104.	0.6	17
92	Overview of Influenza Vaccines in Children. Journal of the Pediatric Infectious Diseases Society, 2013, 2, 368-378.	0.6	13
93	Inactivated Influenza Vaccines for Prevention of Community-Acquired Pneumonia. Epidemiology, 2013, 24, 530-537.	1.2	19
94	Vaccinations for healthcare personnel. Current Opinion in Infectious Diseases, 2013, 26, 366-377.	1.3	8

#	ARTICLE	IF	CITATIONS
95	Influenza vaccines: an Asia-Pacific perspective. <i>Influenza and Other Respiratory Viruses</i> , 2013, 7, 44-51.	1.5	20
96	Assessing vaccine efficacy in influenza clinical trials: challenges and difficulties. <i>Expert Review of Clinical Pharmacology</i> , 2013, 6, 403-411.	1.3	4
97	Preparation of Highly Concentrated Influenza Vaccine for Use in Novel Delivery Approaches. <i>Journal of Pharmaceutical Sciences</i> , 2013, 102, 866-875.	1.6	9
98	Strategies to Achieve the Healthy People 2020 Annual Influenza Vaccine Coverage Goal for Health-Care Personnel: Recommendations from the National Vaccine Advisory Committee. <i>Public Health Reports</i> , 2013, 128, 7-25.	1.3	58
99	Effects of Vaccine Program against Pandemic Influenza A(H1N1) Virus, United States, 2009-2010. <i>Emerging Infectious Diseases</i> , 2013, 19, 439-48.	2.0	63
100	Influenza Vaccines: Unmet Needs and Recent Developments. <i>Infection and Chemotherapy</i> , 2013, 45, 375.	1.0	20
101	The Clinical Characteristics of Influenza B Infection during the 2011-2012 Influenza Season. <i>Korean Journal of Pediatric Infectious Diseases</i> , 2013, 20, 89.	0.1	3
102	Cost-Effectiveness of Alternative Strategies for Annual Influenza Vaccination among Children Aged 6 Months to 14 Years in Four Provinces in China. <i>PLoS ONE</i> , 2014, 9, e87590.	1.1	16
103	<i>Influenza Viruses</i> , 2014, , 455-478.		5
104	Cost-effectiveness analysis of quadrivalent influenza vaccine versus trivalent influenza vaccine for elderly in Hong Kong. <i>BMC Infectious Diseases</i> , 2014, 14, 618.	1.3	37
105	Considerations for the rapid deployment of vaccines against H7N9 influenza. <i>Expert Review of Vaccines</i> , 2014, 13, 1327-1337.	2.0	4
106	Universal immunity to influenza must outwit immune evasion. <i>Frontiers in Microbiology</i> , 2014, 5, 285.	1.5	52
108	Deciding who should get live attenuated influenza vaccine. <i>Reviews in Medical Virology</i> , 2014, 24, 289-290.	3.9	0
109	The burden of influenza-like illness in the US workforce. <i>Occupational Medicine</i> , 2014, 64, 341-347.	0.8	30
110	The time-associated impact of the Newborn Influenza Protection Act on infant influenza rates in New York State. <i>Journal of Perinatal Medicine</i> , 2014, 42, 711-6.	0.6	2
111	Prevention and Control of Seasonal Influenza With Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP)-United States, 2014-15 Influenza Season. <i>American Journal of Transplantation</i> , 2014, 14, 2906-2913.	2.6	137
112	The Effectiveness of <i>Coxiella burnetii</i> Vaccines in Occupationally Exposed Populations: A Systematic Review and Meta-Analysis. <i>Zoonoses and Public Health</i> , 2014, 61, 81-96.	0.9	18
113	Vaccines for preventing influenza in healthy adults. <i>The Cochrane Library</i> , 2014, , CD001269.	1.5	95

#	ARTICLE	IF	CITATIONS
114	The epidemiological impact of childhood influenza vaccination using live-attenuated influenza vaccine (LAIV) in Germany: predictions of a simulation study. <i>BMC Infectious Diseases</i> , 2014, 14, 40.	1.3	43
115	A Versatile RNA Vector for Delivery of Coding and Noncoding RNAs. <i>Journal of Virology</i> , 2014, 88, 2333-2336.	1.5	14
116	<i>Molecular Vaccines</i> . , 2014, , .		1
117	Genome- and proteome-wide screening strategies for antigen discovery and immunogen design. <i>Biotechnology Advances</i> , 2014, 32, 403-414.	6.0	14
118	Vaccinating High-Risk Children with the Intranasal Live-Attenuated Influenza Vaccine: the Quebec Experience. <i>Paediatric Respiratory Reviews</i> , 2014, 15, 340-347.	1.2	6
119	All-in-One Bacmids: an Efficient Reverse Genetics Strategy for Influenza A Virus Vaccines. <i>Journal of Virology</i> , 2014, 88, 10013-10025.	1.5	20
120	Live Attenuated Influenza Vaccine. <i>Current Topics in Microbiology and Immunology</i> , 2014, 386, 181-204.	0.7	58
121	Challenges in mucosal vaccines for the control of infectious diseases. <i>International Immunology</i> , 2014, 26, 517-528.	1.8	94
122	Live viral vaccines in immunocompromised patients. <i>Future Virology</i> , 2014, 9, 161-171.	0.9	6
123	Vaccine-associated reduction in symptom severity among patients with influenza A/H3N2 disease. <i>Vaccine</i> , 2015, 33, 7160-7167.	1.7	55
124	Immunizations in Pediatric and Adult Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 1993-2003.	0.9	20
125	Hemagglutinin Sequence Conservation Guided Stem Immunogen Design from Influenza A H3 Subtype. <i>Frontiers in Immunology</i> , 2015, 6, 329.	2.2	34
126	Influenza (Including Avian Influenza and Swine Influenza). , 2015, , 2000-2024.e6.		15
127	<i>Respiratory Virus Vaccines</i> . , 2015, , 1129-1170.		7
128	Preparation of monoPEGylated Cyanovirin-Nâ€™s derivative and its anti-influenza A virus bioactivity <i>in vitro</i> and <i>in vivo</i>. <i>Journal of Biochemistry</i> , 2015, 157, 539-548.	0.9	14
129	Synthetic Toll-Like Receptor 4 (TLR4) and TLR7 Ligands as Influenza Virus Vaccine Adjuvants Induce Rapid, Sustained, and Broadly Protective Responses. <i>Journal of Virology</i> , 2015, 89, 3221-3235.	1.5	92
130	Maternal Mortality Secondary to Acute Respiratory Failure in Colombia: A Population-Based Analysis. <i>Lung</i> , 2015, 193, 231-237.	1.4	6
131	Targeting PI3K-p110Î± Suppresses Influenza Virus Infection in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015, 191, 1012-1023.	2.5	126



#	ARTICLE	IF	CITATIONS
132	Current Influenza Vaccine Options for 2014. <i>Current Emergency and Hospital Medicine Reports</i> , 2015, 3, 126-133.	0.6	0
133	Neuraminidase: Another Piece of the Influenza Vaccine Puzzle. <i>Journal of Infectious Diseases</i> , 2015, 212, 1180-1181.	1.9	5
134	Antibody to Influenza Virus Neuraminidase: An Independent Correlate of Protection. <i>Journal of Infectious Diseases</i> , 2015, 212, 1191-1199.	1.9	251
135	Profiles of influenza A/H1N1 vaccine response using hemagglutination-inhibition titers. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 961-969.	1.4	37
136	Cost-effectiveness of quadrivalent influenza vaccine in Hong Kong – A decision analysis. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 564-571.	1.4	37
137	Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. <i>Therapeutic Advances in Vaccines</i> , 2015, 3, 97-108.	2.7	86
139	Generation of Live Attenuated Influenza Virus by Using Codon Usage Bias. <i>Journal of Virology</i> , 2015, 89, 10762-10773.	1.5	38
140	Refining the approach to vaccines against influenza A viruses with pandemic potential. <i>Future Virology</i> , 2015, 10, 1033-1047.	0.9	9
142	Deaths averted by influenza vaccination in the U.S. during the seasons 2005/06 through 2013/14. <i>Vaccine</i> , 2015, 33, 3003-3009.	1.7	69
143	Distinct Patterns of B-Cell Activation and Priming by Natural Influenza Virus Infection Versus Inactivated Influenza Vaccination. <i>Journal of Infectious Diseases</i> , 2015, 211, 1051-1059.	1.9	27
145	Public health impact and cost-effectiveness of intranasal live attenuated influenza vaccination of children in Germany. <i>European Journal of Health Economics</i> , 2015, 16, 471-488.	1.4	32
146	<i>Influenza Virus.</i> , 2016, , 1009-1058.		5
147	Influenza and Memory T Cells: How to Awake the Force. <i>Vaccines</i> , 2016, 4, 33.	2.1	30
148	Self-Amplifying mRNA Vaccines Expressing Multiple Conserved Influenza Antigens Confer Protection against Homologous and Heterosubtypic Viral Challenge. <i>PLoS ONE</i> , 2016, 11, e0161193.	1.1	103
149	Quantifying Protection Against Influenza Virus Infection Measured by Hemagglutination-inhibition Assays in Vaccine Trials. <i>Epidemiology</i> , 2016, 27, 143-151.	1.2	22
150	Modest Waning of Influenza Vaccine Efficacy and Antibody Titers During the 2007–2008 Influenza Season. <i>Journal of Infectious Diseases</i> , 2016, 214, 1142-1149.	1.9	57
151	M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice. <i>Vaccine</i> , 2016, 34, 5090-5098.	1.7	32
152	<i>Influenza Vaccines and Vaccination Strategies.</i> , 2016, , 423-444.		4

#	ARTICLE	IF	CITATIONS
153	Prediction of influenza B vaccine effectiveness from sequence data. <i>Vaccine</i> , 2016, 34, 4610-4617.	1.7	6
154	Influenza Virus Detection Following Administration of Live-Attenuated Intranasal Influenza Vaccine in Children With Cystic Fibrosis and Their Healthy Siblings. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw187.	0.4	3
155	Neutralizing Antibody Responses to Antigenically Drifted Influenza A(H3N2) Viruses among Children and Adolescents following 2014-2015 Inactivated and Live Attenuated Influenza Vaccination. <i>Vaccine Journal</i> , 2016, 23, 831-839.	3.2	19
156	Molecular-level analysis of the serum antibody repertoire in young adults before and after seasonal influenza vaccination. <i>Nature Medicine</i> , 2016, 22, 1456-1464.	15.2	271
157	Estimates of the Public Health Impact of a Pediatric Vaccination Program Using an Intranasal Tetravalent Live-Attenuated Influenza Vaccine in Belgium. <i>Paediatric Drugs</i> , 2016, 18, 303-318.	1.3	7
158	Evaluation of the attenuation, immunogenicity, and efficacy of a live virus vaccine generated by codon-pair bias de-optimization of the 2009 pandemic H1N1 influenza virus, in ferrets. <i>Vaccine</i> , 2016, 34, 563-570.	1.7	59
159	Plant-made virus-like particle vaccines bearing the hemagglutinin of either seasonal (H1) or avian (H5) influenza have distinct patterns of interaction with human immune cells in vitro. <i>Vaccine</i> , 2017, 35, 2592-2599.	1.7	21
160	Assessment of Public Health and Economic Impact of Intranasal Live-Attenuated Influenza Vaccination of Children in France Using a Dynamic Transmission Model. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 261-276.	1.0	12
161	Novel Bivalent Viral-Vectored Vaccines Induce Potent Humoral and Cellular Immune Responses Conferring Protection against Stringent Influenza A Virus Challenge. <i>Journal of Immunology</i> , 2017, 199, 1333-1341.	0.4	16
162	Influenza vaccination rates in children decline when the live attenuated influenza vaccine is not recommended. <i>Vaccine</i> , 2017, 35, 5278-5282.	1.7	8
163	Vaccination contre la grippe. <i>Option/Bio</i> , 2017, 28, 14-15.	0.0	0
164	Intranasal Administration of Whole Inactivated Influenza Virus Vaccine as a Promising Influenza Vaccine Candidate. <i>Viral Immunology</i> , 2017, 30, 451-462.	0.6	33
165	The intranasal adjuvant Endocine <sup>®</sup> enhances both systemic and mucosal immune responses in aged mice immunized with influenza antigen. <i>Virology Journal</i> , 2017, 14, 44.	1.4	7
166	Comparisons of the Humoral and Cellular Immune Responses Induced by Live Attenuated Influenza Vaccine and Inactivated Influenza Vaccine in Adults. <i>Vaccine Journal</i> , 2017, 24, .	3.2	106
167	Pneumonia and influenza hospitalizations among children under 5 years of age in Suzhou, China, 2005-2011. <i>Influenza and Other Respiratory Viruses</i> , 2017, 11, 15-22.	1.5	15
168	Influenza and pneumococcal vaccination in older adults living in nursing home: a survival analysis on the shelter study. <i>European Journal of Public Health</i> , 2017, 27, 1016-1020.	0.1	10
169	Moving Toward Improved Influenza Vaccines. <i>Journal of Infectious Diseases</i> , 2017, 215, 500-502.	1.9	7
170	Influenza Viruses. , 2018, , 1181-1190.e5.		2

#	ARTICLE	IF	CITATIONS
171	Vaccines for preventing influenza in healthy adults. The Cochrane Library, 2020, 2020, CD001269.	1.5	140
172	Seasonal Incidence of Symptomatic Influenza in the United States. <i>Clinical Infectious Diseases</i> , 2018, 66, 1511-1518.	2.9	179
173	Estimating the annual attack rate of seasonal influenza among unvaccinated individuals: A systematic review and meta-analysis. <i>Vaccine</i> , 2018, 36, 3199-3207.	1.7	118
174	Management of community-acquired pneumonia in immunocompetent adults: updated Swedish guidelines 2017. <i>Infectious Diseases</i> , 2018, 50, 247-272.	1.4	36
175	Urgent challenges in implementing live attenuated influenza vaccine. <i>Lancet Infectious Diseases</i> , The, 2018, 18, e25-e32.	4.6	46
176	Topical Application of a Vitamin A Derivative and Its Combination With Non-ablative Fractional Laser Potentiates Cutaneous Influenza Vaccination. <i>Frontiers in Microbiology</i> , 2018, 9, 2570.	1.5	6
177	Estimating Vaccine-Driven Selection in Seasonal Influenza. <i>Viruses</i> , 2018, 10, 509.	1.5	8
178	To mist or not to mist: An update on the recommendations for live-attenuated influenza vaccine. <i>Journal of the American Pharmacists Association: JAPhA</i> , 2018, 58, 457-459.	0.7	1
179	Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity. <i>Vaccine</i> , 2018, 36, 5097-5103.	1.7	24
180	Live Attenuated Influenza Vaccine: Is Past Performance a Guarantee of Future Results?. <i>Clinical Therapeutics</i> , 2018, 40, 1246-1254.	1.1	10
181	Inactivated Influenza Vaccines. , 2018, , 456-488.e21.		14
182	Influenza Vaccineâ€”Live. , 2018, , 489-510.e7.		2
183	Understanding influenza vaccine perspectives and hesitancy in university students to promote increased vaccine uptake. <i>Heliyon</i> , 2019, 5, e02604.	1.4	53
184	HAI and NAI titer correlates of inactivated and live attenuated influenza vaccine efficacy. <i>BMC Infectious Diseases</i> , 2019, 19, 453.	1.3	23
185	Influenza Vaccine Effectiveness: Defining the H3N2 Problem. <i>Clinical Infectious Diseases</i> , 2019, 69, 1817-1823.	2.9	81
186	How Live Attenuated Vaccines Can Inform the Development of Broadly Cross-Protective Influenza Vaccines. <i>Journal of Infectious Diseases</i> , 2019, 219, S81-S87.	1.9	11
187	Effectiveness of the Live Attenuated Influenza Vaccine: Was the Addition of the Second Type B Lineage a Step Too Far?. <i>Clinical Infectious Diseases</i> , 2020, 70, 2514-2516.	2.9	6
188	Understanding Immunity in Children Vaccinated With Live Attenuated Influenza Vaccine. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, S10-S14.	0.6	12

#	ARTICLE	IF	CITATIONS
189	Sex, Age, and Race Effects on Immunogenicity of MenB-FHbp, A Bivalent Meningococcal B Vaccine: Pooled Evaluation of Clinical Trial Data. <i>Infectious Diseases and Therapy</i> , 2020, 9, 625-639.	1.8	3
190	Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. <i>Human Vaccines and Immunotherapeutics</i> , 2020, 16, 2921-2931.	1.4	85
191	Immune Response and Protective Efficacy of Inactivated and Live Influenza Vaccines Against Homologous and Heterosubtypic Challenge. <i>Biochemistry (Moscow)</i> , 2020, 85, 553-566.	0.7	2
192	Optimizing Vaccination in Adult Patients With Liver Disease and Liver Transplantation. <i>Clinical Liver Disease</i> , 2020, 15, 63-68.	1.0	12
193	History of Live, Attenuated Influenza Vaccine. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2020, 9, S3-S9.	0.6	3
194	Live Attenuated Cold-Adapted Influenza Vaccines. <i>Cold Spring Harbor Perspectives in Medicine</i> , 2020, 11, a038653.	2.9	9
195	Influenza Vaccination: Accelerating the Process for New Vaccine Development in Older Adults. <i>Interdisciplinary Topics in Gerontology and Geriatrics</i> , 2020, 43, 98-112.	2.6	6
196	Seasonal Variability and Shared Molecular Signatures of Inactivated Influenza Vaccination in Young and Older Adults. <i>Journal of Immunology</i> , 2020, 204, 1661-1673.	0.4	28
197	An Appraisal of the Current Scenario in Vaccine Research for COVID-19. <i>Viruses</i> , 2021, 13, 1397.	1.5	6
198	Modeling human adaptive immune responses with tonsil organoids. <i>Nature Medicine</i> , 2021, 27, 125-135.	15.2	133
199	Live Attenuated Influenza Vaccine. , 2011, , 273-291.		2
200	Influenza Cell-Culture Vaccine Production. , 2014, , 823-837.		4
201	Influenza Viruses. , 2012, , 1149-1159.e7.		7
202	Age-related increases in PGD2 expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. <i>Journal of Clinical Investigation</i> , 2011, 121, 4921-4930.	3.9	228
203	Pneumococcal and influenza vaccination. , 2014, , 266-284.		6
204	Incidence of Influenza in Healthy Adults and Healthcare Workers: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2011, 6, e26239.	1.1	184
205	Impact of Preventive Responses to Epidemics in Rural Regions. <i>PLoS ONE</i> , 2013, 8, e59028.	1.1	5
206	Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the United States, 2005–2011. <i>PLoS ONE</i> , 2013, 8, e66312.	1.1	173

#	ARTICLE	IF	CITATIONS
207	Vaccination has minimal impact on the intrahost diversity of H3N2 influenza viruses. PLoS Pathogens, 2017, 13, e1006194.	2.1	90
208	Recommendations on the use of live, attenuated influenza vaccine (FluMist®): supplemental statement on seasonal influenza vaccine for 2011-2012. Canada Communicable Disease Report, 2011, 37, 1-77.	0.6	10
209	Prevention and Control of Seasonal Influenza with Vaccines. MMWR Recommendations and Reports, 2016, 65, 1-54.	26.7	357
210	Strengths and limitations of assessing influenza vaccine effectiveness using routinely collected, passive surveillance data in Ontario, Canada, 2007 to 2012: balancing efficiency versus quality. Eurosurveillance, 2015, 20, .	3.9	8
212	Influenza Vaccines: The Key to Disease Prevention and Control. Pediatric Annals, 2009, 38, 650-654.	0.3	0
214	Perceived Risks from Live Viral Vaccines. , 2013, , 235-254.		0
215	Neue Arzneimittel 2012. , 2013, , 47-120.		1
217	Live viral vaccines in transplanted patients. Swiss Medical Weekly, 2014, 144, w14005.	0.8	8
219	Immunization Update. Journal of Contemporary Pharmacy Practice, 2017, 64, 24-27.	0.2	0
221	Clinical practice guidelines 2019: Indian consensus-based recommendations on influenza vaccination in adults. Lung India, 2020, 37, 4.	0.3	7
222	Influenza. Clinical Evidence, 2011, 2011, .	0.2	0
223	Strategies to achieve the healthy people 2020 annual influenza vaccine coverage goal for health-care personnel: recommendations from the national vaccine advisory committee. Public Health Reports, 2013, 128, 7-25.	1.3	31
224	Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices (ACIP) -- United States, 2014-15 influenza season. Morbidity and Mortality Weekly Report, 2014, 63, 691-7.	9.0	223
225	Particulate vaccines against SARS-CoV-2. , 2022, , 153-171.		1
227	Development of a safe and effective novel synthetic mucosal adjuvant SF-10 derived from physiological metabolic pathways and function of human pulmonary surfactant. Vaccine, 2022, 40, 544-553.	1.7	2
228	Estimation of Relative Vaccine Effectiveness in Influenza: A Systematic Review of Methodology. Epidemiology, 2022, 33, 334-345.	1.2	10
229	The unfulfilled potential of mucosal immunization. Journal of Allergy and Clinical Immunology, 2022, 150, 1-11.	1.5	11
230	A live attenuated virus-based intranasal COVID-19 vaccine provides rapid, prolonged, and broad protection against SARS-CoV-2. Science Bulletin, 2022, 67, 1372-1387.	4.3	54

#	ARTICLE	IF	CITATIONS
231	Systematic Review on the Cost-Effectiveness of Seasonal Influenza Vaccines in Older Adults. Value in Health, 2022, 25, 1439-1458.	0.1	7
233	Sex and prior exposure jointly shape innate immune responses to a live herpesvirus vaccine. ELife, 0, 12, .	2.8	3
234	Revisiting live attenuated influenza vaccine efficacy among children in developing countries. Vaccine, 2023, , .	1.7	0
235	Immune interference in effectiveness of influenza and COVID-19 vaccination. Frontiers in Immunology, 0, 14, .	2.2	7
236	Influenza Viruses. , 2023, , 1-57.		0
237	Influenza Viruses. , 2023, , 1-57.		0
240	Influenza Vaccineâ€™Live. , 2023, , 552-576.e8.		0
241	Inactivated and Recombinant Influenza Vaccines. , 2023, , 514-551.e31.		0